Sugi Predict
/ Targets
/ YWHAZ
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to YWHAZ by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients |
PHASE3 | COMPLETED |
| NG2 and DLL3 CAR-T Cells Targeting Melanoma |
PHASE1/PHASE2 | RECRUITING |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
PHASE2 | COMPLETED |
| Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia |
PHASE1/PHASE2 | COMPLETED |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia |
PHASE2 | COMPLETED |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease |
PHASE2 | COMPLETED |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer |
PHASE2 | COMPLETED |
| Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment |
PHASE2 | COMPLETED |
| Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome |
PHASE2 | COMPLETED |
| A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
PHASE2 | COMPLETED |
| GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma |
PHASE2 | ACTIVE_NOT_RECRUITING |
| CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 |
PHASE2 | COMPLETED |
| 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma |
PHASE1 | COMPLETED |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
EARLY_PHASE1 | COMPLETED |
| Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity |
nan | COMPLETED |
| Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome |
nan | ACTIVE_NOT_RECRUITING |
| Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis |
nan | COMPLETED |
| Semen Analysis Changes in Covid-19 Positivepatients |
nan | COMPLETED |
| X-chromosome Inactivation, Epigenetics and the Transcriptome |
nan | COMPLETED |
| Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma |
nan | COMPLETED |
| Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study |
nan | COMPLETED |
| The Clinical Study of Sex Chromosome Variants |
nan | COMPLETED |
| Chromosome 9 P Minus Syndrome |
nan | RECRUITING |
| Phenotypic Properties in Individuals Affected With XLHED |
nan | COMPLETED |
| IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? |
nan | UNKNOWN |
| SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs) |
nan | RECRUITING |
| Blood-based Biomarkers for the Prognosis of Sports Related Concussion |
nan | COMPLETED |
| Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure |
nan | RECRUITING |
| Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a YWHAZ binder may also engage these)